Carglumic acid

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Carglumic acid
File:Carglumic acid.svg
Systematic (IUPAC) name
(2S)-2-(carbamoylamino)pentanedioic acid
Clinical data
AHFS/Drugs.com Consumer Drug Information
Licence data EMA:Link
Pregnancy
category
  • unknown
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 30%
Protein binding Undetermined
Metabolism Partial
Biological half-life 4.3 to 9.5 hours
Excretion Fecal (60%) and renal (9%, unchanged)
Identifiers
CAS Number 1188-38-1 N
ATC code A16AA05 (WHO)
PubChem CID: 121396
IUPHAR/BPS 7458
DrugBank DB06775 YesY
ChemSpider 1265942 N
UNII 5L0HB4V1EW N
KEGG D07130 YesY
ChEBI CHEBI:71028 N
ChEMBL CHEMBL1201780 N
Synonyms (S)-2-ureidopentanedioic acid
Chemical data
Formula C6H10N2O5
Molecular mass 190.2 g/mol
  • C(CC(=O)O)[C@@H](C(=O)O)NC(=O)N
  • InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1 YesY
  • Key:LCQLHJZYVOQKHU-VKHMYHEASA-N YesY
 NYesY (what is this?)  (verify)

Carglumic acid is an orphan drug, marketed by Orphan Europe under the trade name Carbaglu. Carglumic acid is used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency.[1][2] The initial daily dose ranges from 100 to 250 mg/kg, adjusted thereafter to maintain normal plasma levels of ammonia.

The US FDA approved it for treatment of hyperammonaemia on March 18, 2010. Orphan Drug exclusivity expires on March 18,2017.[3]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Carglumic_acid&oldid=4871920"